Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy
- 1 December 2022
- journal article
- editorial
- Published by Wiley in American Journal of Hematology
- Vol. 98 (2) , 361-364
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman diseaseJournal of Clinical Investigation, 2019
- Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseasePLOS ONE, 2019
- Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?American Journal of Hematology, 2019
- Tafro syndrome: Critical review for clinicians and pathologistsCritical Reviews in Oncology/Hematology, 2018
- International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman diseaseBlood, 2017
- Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndromeScientific Reports, 2017
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2014
- Clinical Implications of Idiopathic Multicentric Castleman Disease Among Japanese: A Report of 28 CasesInternational Journal of Surgical Pathology, 2008
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Hyaline‐vascular and plasma‐cell types of giant lymph node hyperplasia of the mediastinum and other locationsCancer, 1972